Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
Clinical Infectious Diseases · 06.01.2023 · 76 (1) · 66-77
DOI: 10.1093/cid/ciac738 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 07.09.2022. Verfasst von Michael W Dunne und 6 weiteren Autor:innen. Beteiligte Einrichtung: Iterum Therapeutics, Old Saybrook, Connecticut, USA. Hauptthemen laut MEDLINE: Ciprofloxacin, Urinary Tract Infections. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Iterum Therapeutics reported by K. A..
Abstract (Originalsprache)
Background
There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens that cause uUTIs.
Methods
Patients with uUTI were randomized to 5 days of sulopenem or 3 days of ciprofloxacin. The primary endpoint was overall success, defined as both clinical and microbiologic response at day 12. In patients with ciprofloxacin-nonsusceptible baseline pathogens, sulopenem was compared for superiority over ciprofloxacin; in patients with ciprofloxacin-susceptible pathogens, the agents were compared for noninferiority. Using prespecified hierarchical statistical testing, the primary endpoint was tested in the combined population if either superiority or noninferiority was declared in the nonsusceptible or susceptible population, respectively.
Results
In the nonsusceptible population, sulopenem was superior to ciprofloxacin, 62.6% vs 36.0% (difference, 26.6%; 95% confidence interval [CI], 15.1 to 7.4; P <.001). In the susceptible population, sulopenem was not noninferior to ciprofloxacin, 66.8% vs 78.6% (difference, −11.8%; 95% CI, −18.0 to 5.6). The difference was driven by a higher rate of asymptomatic bacteriuria (ASB) post-treatment in patients on sulopenem. In the combined analysis, sulopenem was noninferior to ciprofloxacin, 65.6% vs 67.9% (difference, −2.3%; 95% CI, −7.9 to 3.3). Diarrhea occurred more frequently with sulopenem (12.4% vs 2.5%).
Conclusions
Sulopenem was noninferior to ciprofloxacin in the treatment of uUTIs. Sulopenem was superior to ciprofloxacin in patients with uUTIs due to ciprofloxacin-nonsusceptible pathogens. Sulopenem was not noninferior in patients with ciprofloxacin-susceptible pathogens, driven largely by a lower rate of ASB in those who received ciprofloxacin. Clinical Trial Registration NCT03354598.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Iterum Therapeutics, Old Saybrook, Connecticut, USA.
- Das Statistical Consulting, Guerneville, California, USA.
- Tufts Medicine and Tufts University School of Medicine, Boston Massachusetts, USA.
ORCID-Profile: Michael W Dunne
Förderung
- Iterum Therapeutics reported by K. A.
Zitieren
APA
Dunne, M. W., Aronin, S. I., Das, A. F., Akinapelli, K., Zelasky, M. T., Puttagunta, S., & Boucher, H. W. (2023). Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial. Clinical Infectious Diseases, 76(1), 66-77. https://doi.org/10.1093/cid/ciac738
Vancouver
Dunne MW, Aronin SI, Das AF, Akinapelli K, Zelasky MT, Puttagunta S, et al. Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial. Clinical Infectious Diseases. 2023;76(1):66-77. doi:10.1093/cid/ciac738
BibTeX
@article{Dunne2023,
author = {Dunne, Michael W and Aronin, Steven I and Das, Anita F and Akinapelli, Karthik and Zelasky, Michael T and Puttagunta, Sailaja and Boucher, Helen W},
title = {Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {1},
pages = {66--77},
doi = {10.1093/cid/ciac738}
}
EUVIMED